Start free

Lycia Therapeutics, Inc. (LYCA) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 4, 2026.

Filings shown
12
Open-market buys
12
Open-market sells
0
Buys, 10b5-1 box not checked
12 of 12

Counts cover the 12 most recent Form 4 filings Tradune holds for LYCA (filed Oct 26 – Nov 4, 2026). SEC EDGAR Form 4 filings for LYCA last checked Nov 21, 2026, 09:00 UTC; the latest LYCA filing Tradune holds was filed Nov 4, 2026. This is not guaranteed to be the complete record — see LYCA's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 12 filings Tradune holds for LYCA filed Oct 26 – Nov 4, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Venrock Healthcare Capital Partners III, L.P.10% owner 12 0 2,078,749 — +$38,522,394

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

39/ 100

Net insider purchases
1 distinct buyer11 buy · 0 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at LYCA

Insiders reported 12 open-market purchases of LYCA in the trailing 90 days, across 1 distinct buyer. The most recent purchase was reported by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 2, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Venrock Healthcare Capital Partners III, L.P. 10% owner · filed Nov 4, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 8,305 $26.95 6,858,542 (indirect) +0.1% Nov 2, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Venrock Healthcare Capital Partners III, L.P. 10% owner · filed Oct 30, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 200 $26.86 6,850,237 (indirect) +0.0% Oct 30, 2026
Open-market purchase 10b5-1 box not checked 8,804 $26.27 6,850,037 (indirect) +0.1% Oct 30, 2026
Open-market purchase 10b5-1 box not checked 1,000 $26.33 6,841,233 (indirect) +0.0% Oct 29, 2026
Open-market purchase 10b5-1 box not checked 4,430 $25.97 6,840,233 (indirect) +0.1% Oct 28, 2026
Open-market purchase 10b5-1 box not checked 10,570 $25.23 6,835,803 (indirect) +0.2% Oct 28, 2026
Versant Ventures Vii GP, L.P. 10% owner · filed Oct 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative Series A Preferred Stock 25,390,410 — — — Oct 26, 2026
Conversion of derivative Series B Preferred Stock 6,284,597 — — — Oct 26, 2026
Conversion of derivative 5,631,425 — 5,631,425 (indirect) — Oct 26, 2026
Conversion of derivative 1,393,882 — 1,393,882 (indirect) — Oct 26, 2026
Venrock Healthcare Capital Partners III, L.P. 10% owner · filed Oct 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 8,729 $25.84 6,794,166 (indirect) +0.1% Oct 27, 2026
Open-market purchase 10b5-1 box not checked 31,067 $26.84 6,825,233 (indirect) +0.5% Oct 27, 2026
Open-market purchase 10b5-1 box not checked 8,261 $26.97 6,785,437 (indirect) +0.1% Oct 26, 2026
Conversion of derivative Series C Preferred Stock 17,142,578 — — — Oct 26, 2026
Conversion of derivative Series D Preferred Stock 4,408,091 — — — Oct 26, 2026
Open-market purchase 10b5-1 box not checked 1,944,444 $18.00 6,777,176 (indirect) +40% Oct 26, 2026
Conversion of derivative 4,779,793 — 4,832,732 (indirect) +9,029% Oct 26, 2026
Open-market purchase 10b5-1 box not checked 24,560 $25.68 24,560 (indirect) — Oct 23, 2026
Open-market purchase 10b5-1 box not checked 28,379 $26.11 52,939 (indirect) +116% Oct 23, 2026
Jane Henderson Director · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 20,000 — — — Oct 22, 2026
Grant / award Stock Option (Right to Buy) 57,666 — — — Aug 11, 2026
Laurent Fischer Director · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 20,000 — — — Oct 22, 2026
Grant / award Stock Option (Right to Buy) 13,307 — — — Aug 11, 2026
William Jl Rieflin Director · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 20,000 — — — Oct 22, 2026
Grant / award Stock Option (Right to Buy) 24,840 — — — Aug 11, 2026
Sofia Touami Chief Business Officer · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 68,755 — — — Aug 11, 2026
Steven Staben Chief Scientific Officer · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 110,896 — — — Aug 11, 2026
Amy Bachrodt Chief Financial Officer · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 399,746 — — — Aug 11, 2026
Chin Hyok Lee Chief Medical Officer · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 73,191 — — — Aug 11, 2026
Aetna Wun Trombley President and CEO · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 443,586 — — — Aug 11, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to LYCA's (Nov 4, 2026).

Frequently asked about LYCA insider activity

How many insiders bought LYCA stock in the last 90 days?

1 distinct insider at Lycia Therapeutics, Inc. reported 12 open-market purchases (Form 4 code P) of LYCA shares in the trailing 90 days, the most recent filed by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 2, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for LYCA?

The most recent Form 4 on this page was filed by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 4, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market LYCA insider purchase shown?

The largest open-market purchase among the filings shown was 1,944,444 LYCA shares at $18.00 (about $34,999,992) by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Oct 26, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent LYCA insider purchases have the Form 4 10b5-1 box checked?

No. All 12 LYCA open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 2, 2026, 8,305 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for LYCA — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.